홈 > BT동향 > 특허동향
|GSK publishes 2008 Corporate Responsibility Report|
GSK publishes 2008 Corporate Responsibility Report
- Details on new proposals to tackle diseases of the developing world
- New commitments to enhance transparency to facilitate clinical research
- Charitable support increased by 13%
In its Corporate Responsibility Report published today, GSK reiterated its commitment to running its business responsibly and transparently. GSK provided an update on how it will work to improve access to medicines in the developing world and further details about initiatives outlined in February. The company announced additional steps to build on its commitment to the transparency of clinical research data and the public disclosure of its financial interactions with healthcare professionals. It also reported a substantive increase in its level of charitable support.
Commenting on the report, Andrew Witty, CEO of GlaxoSmithKline said: “We recognise that GSK has unique and privileged capabilities. Continually strengthening our contract with society is vitally important and this is why we are fully committed to operating to the highest ethical standards. This report emphasises our determination to do just that - whether it is by cutting prices in the world's poorest countries, being more flexible with our intellectual property to encourage more research into neglected diseases, or increasing transparency to facilitate clinical research. As we move forward, we will continue to look for new ways and new partnerships to improve global public health and research."....계속
☞ 자세한 내용은 첨부파일을 참고하시기 바랍니다.
친구에게 이 자료를 추천하기
|한국파스퇴르연구소, 글락소스미스클라인(GSK)이 후원하는 결핵 치료제 개발 국제공동연구(Open Lab.) 착수||2013-05-02|
|세포노화에 동반되는 비정상적 신진대사와 GSK3의 역할||2011-05-13|
|[BioINdustry_No.32] 주요 제약 기업(PFE, MRK, GSK, NVS) 분석 1||2011-05-09|
|GSK publishes 2008 Corporate Responsibility Report||2009-04-06|
|[BioWatch 주간 2009-2호] GSK, 혈소판 관련치료제 임상 3 긍정적, Apthera, 냉동건조상태의 항암제 임상3 착수 등..||2008-12-15|